ubet63 free 100 no deposit bonus
Mbappé enduring 'difficult moment' as he misses another penalty kick and Madrid loses to Athletic49ers RB Christian McCaffrey on knee injury, 'humbling' season: 'Wasn't my year'
Highlanders kick off season with win over Warriors, 48-37Counting is underway in Ireland's election as 3 parties battle for top place
White House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaign
Advisors Asset Management Inc. lowered its stake in shares of Horace Mann Educators Co. ( NYSE:HMN – Free Report ) by 61.6% in the third quarter, Holdings Channel reports. The institutional investor owned 3,817 shares of the insurance provider’s stock after selling 6,124 shares during the period. Advisors Asset Management Inc.’s holdings in Horace Mann Educators were worth $133,000 as of its most recent filing with the SEC. Other hedge funds have also made changes to their positions in the company. Quarry LP increased its stake in Horace Mann Educators by 1,798.0% during the second quarter. Quarry LP now owns 949 shares of the insurance provider’s stock valued at $31,000 after acquiring an additional 899 shares during the period. GAMMA Investing LLC increased its position in shares of Horace Mann Educators by 142.1% during the third quarter. GAMMA Investing LLC now owns 920 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 540 shares during the period. Summit Securities Group LLC bought a new stake in shares of Horace Mann Educators during the second quarter valued at approximately $35,000. KBC Group NV raised its stake in shares of Horace Mann Educators by 60.2% in the third quarter. KBC Group NV now owns 1,671 shares of the insurance provider’s stock valued at $58,000 after purchasing an additional 628 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in Horace Mann Educators during the second quarter worth $59,000. Institutional investors own 99.28% of the company’s stock. Analysts Set New Price Targets A number of equities analysts have recently issued reports on HMN shares. Raymond James began coverage on shares of Horace Mann Educators in a research note on Tuesday, August 6th. They issued a “strong-buy” rating and a $42.00 price objective for the company. Keefe, Bruyette & Woods lowered shares of Horace Mann Educators from an “outperform” rating to a “market perform” rating and increased their price target for the stock from $39.00 to $44.00 in a research report on Tuesday, November 12th. Finally, Piper Sandler increased their price target on Horace Mann Educators from $36.00 to $42.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Four equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Horace Mann Educators presently has an average rating of “Hold” and a consensus target price of $42.67. Insider Transactions at Horace Mann Educators In related news, Director Beverley J. Mcclure sold 5,634 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $42.08, for a total transaction of $237,078.72. Following the sale, the director now owns 19,057 shares in the company, valued at approximately $801,918.56. This represents a 22.82 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink . Also, CEO Marita Zuraitis sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $37.24, for a total value of $148,960.00. Following the completion of the transaction, the chief executive officer now owns 292,336 shares of the company’s stock, valued at approximately $10,886,592.64. This represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold a total of 51,751 shares of company stock worth $1,946,895 in the last three months. Insiders own 3.80% of the company’s stock. Horace Mann Educators Price Performance Shares of HMN stock opened at $41.89 on Friday. The firm’s 50 day moving average price is $37.91 and its two-hundred day moving average price is $35.31. The stock has a market cap of $1.71 billion, a PE ratio of 16.69 and a beta of 0.27. Horace Mann Educators Co. has a 52-week low of $31.81 and a 52-week high of $43.26. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.09 and a current ratio of 0.09. Horace Mann Educators ( NYSE:HMN – Get Free Report ) last posted its earnings results on Monday, November 4th. The insurance provider reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. Horace Mann Educators had a return on equity of 8.14% and a net margin of 6.55%. The firm had revenue of $412.10 million during the quarter, compared to analysts’ expectations of $293.87 million. During the same period in the previous year, the firm earned $0.44 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. As a group, analysts forecast that Horace Mann Educators Co. will post 2.61 EPS for the current year. Horace Mann Educators Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 16th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Monday, September 16th. This represents a $1.36 annualized dividend and a yield of 3.25%. Horace Mann Educators’s dividend payout ratio (DPR) is presently 54.18%. Horace Mann Educators Profile ( Free Report ) Horace Mann Educators Corporation, together with its subsidiaries, operates as an insurance holding company in the United States. The company operates through Property & Casualty, Life & Retirement, and Supplemental & Group Benefits segments. Its Property & Casualty segment offers insurance products, including private passenger auto insurance, residential home insurance, and personal umbrella insurance; and provides auto coverages including liability and collision, and property coverage for homeowners and renters. Featured Stories Want to see what other hedge funds are holding HMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horace Mann Educators Co. ( NYSE:HMN – Free Report ). Receive News & Ratings for Horace Mann Educators Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horace Mann Educators and related companies with MarketBeat.com's FREE daily email newsletter .
Creator of the Chill Guy meme threatens takedowns after doxxing, crypto coin surge
Offense rules day as No. 10 Georgia dispatches MassachusettsConcurrent Gainers: 10 midcap stocks that gain for 5 days in a row - The Economic TimesKansas State vs. Iowa State FREE LIVE STREAM (11/30/24): Watch college football, Week 14 online | Time, TV, channel
TTM Technologies, Inc. Introduces Innovative Radio Frequency Components for Telecom Band n104 to Enhance 5.5G Applications
Plans Required to Cover Treatment for SOD1-ALS ARLINGTON, Va. , Dec. 11, 2024 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) has announced a first-of-its-kind directive requiring Medicare Advantage plans to approve coverage for Qalsody, a treatment for people living with genetic SOD1-ALS. This decision reflects the ALS Association's commitment to ensuring that people living with ALS have access to promising ALS treatments without delay. "This is a victory for the entire ALS community," said Calaneet Balas, president and CEO of the ALS Association. "It's critical that FDA-approved treatments are made accessible rather than being labeled as 'experimental.' We are grateful to everyone in our community who helped make this day happen." Balas added: "We hope this sends a message to the entire rare disease community and pharmaceutical industry that new treatments can be developed and made accessible to those who will benefit from them. We need to ensure more ALS treatments are developed and approved that will help everyone living with ALS." The ALS Association played a key role in the historic CMS directive by participating and advocating for the research, approval, and accessibility of Qalsody for people living with ALS. In 2004, the ALS Association was the first to fund research into ALS-specific antisense oligonucleotide (ASO) technology, investing over $1.3 million in groundbreaking studies that laid the foundation for the development of Qalsody. This early commitment supported preclinical studies, safety trials, and the first-in-human phase 1 trial, which established SOD1 as a viable therapeutic target. In 2023, Qalsody became the first gene-based therapy approved for ALS , thanks in part to the ALS Association's efforts, including a united push from the ALS community for FDA accelerated approval. This new CMS directive provides precedent for state regulators to issue similar actions for other private insurers. According to the Valor study published in 2022 , Qalsody, which was developed specifically to target the RNA produced by mutated SOD1 genes, has demonstrated significant promise in clinical trials and real-world studies. In the phase 3 VALOR trial, Qalsody reduced levels of mutated SOD1 proteins in cerebral spinal fluid by 35% within eight weeks and decreased bloodstream levels of neurofilament light chain (NfL)—a key biomarker of neurodegeneration—by 50% within 12-16 weeks. These biological changes translated into measurable clinical benefits, including slower disease progression, improved respiratory function, and enhanced quality of life after 52 weeks of treatment. Real-world data has since validated these findings, with some patients stabilizing or even experiencing improvements in motor function and quality of life. When insurance companies began denying access to Qalsody, labeling it as "experimental," the ALS Association took decisive action, working directly with CMS to launch an investigation into these unjust denials. By presenting evidence of widespread insurance rejections and demonstrating the critical need for immediate intervention. In addition to working with CMS, the ALS Association actively engaged policymakers, held strategic meetings with state and federal legislators, and served as a staunch advocate for patients, ensuring their voices were heard and their rights to life-changing treatment were upheld. The ALS Association urges anyone previously denied Qalsody by their Medicare Advantage plan to contact their ALS specialist immediately to begin the process of securing access to this critical treatment. For more information on the CMS directive visit als.org About the ALS Association The ALS Association is the largest ALS organization in the world. The ALS Association funds global research collaborations, assists people with ALS and their families through its nationwide network of care and certified clinical care centers, and advocates for better public policies for people with ALS. The ALS Association is working to make ALS a livable disease while urgently searching for new treatments and a cure. For more information about the ALS Association, visit our website at www.als.org . About ALS Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. The disease is always fatal, usually within five years of diagnosis. Few treatment options exist, resulting in a high unmet need for new therapies to address functional deficits and disease progression. View original content to download multimedia: https://www.prnewswire.com/news-releases/groundbreaking-directive-ensures-als-patients-on-medicare-advantage-gain-access-to-qalsody-302329525.html SOURCE The ALS Association
"Tipu Sultan Is Actually A Very Complex Figure In History": S JaishankarNEW YORK (AP) — Ayden Pereira rushed for 136 yards on 17 carries and threw for a touchdown and Merrimack's defense smothered Fordham 19-3 in a season finale. Jay Thompson had three solo sacks and was credited with four of Merrimack’s 11 sacks. The Rams (2-10) finished with just four first downs and were held to minus-29 yards rushing and 31 total yards offense. The Warriors (5-6) also made two interceptions. Pereira was 12-of-15 passing for 131 yards, connecting with Jalen McDonald for a 12-yard touchdown and a 16-3 lead late in the third quarter. Lliam Davis's field goal made it 19-3 in the fourth quarter. After Kendal Sims blocked a Fordham punt out of the end zone for a safety, Jermaine Corbett went over from a yard out for a 9-0 lead in the first quarter. Bennett Henderson had Fordham's only points with a 43-yard field goal. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football . Sign up for the AP’s college football newsletter: https://apnews.com/cfbtop25